Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent squamous cell carcinoma of the head and neck

Michelle I. Echevarria,George Q. Yang,Dung-Tsa Chen,Kedar Kirtane,Jeffery Russell,Julie Kish,Jameel Muzaffar,Kristen Otto,Tapan Padhya,Caitlin McMullen,Krupal Patel,Christine H. Chung,Jimmy J. Caudell

International Journal of Radiation Oncology*Biology*Physics（2023）

引用 2|浏览21

暂无评分

摘要

Concurrent cisplatin and re-irradiation with SBRT up to a dose of 40 Gy was safe and feasible in patients locoregionally recurrent or second primary SCCHN.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要